# Task C1: Phase I Clinical Trial to Evaluate Influenza Therapeutics

> **NIH NIH N01** · ALLUCENT GOVERNMENT SERVICES (US) LLC · 2024 · $3,205,231

## Abstract

The Early Phase Clinical Trial Units provide a vehicle for investigation of new agents in the treatment and prevention of infectious diseases and can carry out all aspects of interventional clinical trial implementation.

## Key facts

- **NIH application ID:** 11202303
- **Project number:** 75N93022D00015-0-759302400001-1
- **Recipient organization:** ALLUCENT GOVERNMENT SERVICES (US) LLC
- **Principal Investigator:** MCCLENATHAN BRUCE
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $3,205,231
- **Award type:** —
- **Project period:** 2024-08-15 → 2024-11-01

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11202303

## Citation

> US National Institutes of Health, RePORTER application 11202303, Task C1: Phase I Clinical Trial to Evaluate Influenza Therapeutics (75N93022D00015-0-759302400001-1). Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/grant/nih/11202303. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*